Myocytes, also known as a muscle cells. Discovery Drive-based synthetic biology specialist Bit Bio has closed a $41.5million Series A investment, bringing the company’s total funding to $50million. The investment was led by three of the world’s top life sciences...
Rick Klausner, Bob Nelsen, and Jim Tananbaum team up with Bit Bio to uncover the “operating system of life” and accelerate the company’s drive towards industrial-scale manufacturing of all human cells CAMBRIDGE, 13 June — Bit Bio, a Cambridge-based synthetic biology...
Webinar – on demand Speakers: Prof Hagan Bayley & Dr Mark Kotter Monday June 29 4pm GMT | 8am PST | 11am EST 60 minutes Listen to our latest webinar! A scalable technology platform capable of producing consistent batches of every human cell has the...
Join us at ISSCR 2020 where we will be exhibiting! The ISSCR Annual Meeting gathers the world’s leading scientists, clinicians, business leaders, ethicists, and educators from more than 65 countries. Together, they represent the full spectrum of...
CAMBRIDGE, England, Feb. 25, 2020 /PRNewswire/ — Bit Bio announces agreement with Abcam, a global innovator in life science reagents and tools, to make Bit Bio’s iPSC derived functional human cells widely available to the global life science community....
Partnership will leverage Bit Bio’s unique ability to generate authentic human cells at scale WILMINGTON, Mass.–(BUSINESS WIRE)–Dec. 10, 2019– Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
